NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization291 mln
Float69.93 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
8.33
Transformational upside
Relative Strength
79
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-120
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Eledon Pharmaceuticals is a clinical-stage biotech company based in Irvine, California, focused on developing treatments that work by blocking the CD40L biological pathway. Its primary drug candidate, tegoprubart, is being studied for its ability to prevent the body from rejecting transplanted kidneys and to treat ALS, a progressive neurological disease. The company also works with partners eGenesis and NewcelX on additional programs, including a cell-based treatment for Type 1 Diabetes.
